Physician profile
Saul Torres
NPI 1952573776
$10,840.60
in general payments reported to CMS, 2019-2025
25 companies · $7,673 in 2025
The $7,673 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $394 · 2020: $20.74 · 2021: $242 · 2022: $610 · 2023: $997 · 2024: $905 · 2025: $7,673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,529 · Food and Beverage: $3,219 · Travel and Lodging: $827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,529.17 |
| Food and Beverage | $3,218.62 |
| Travel and Lodging | $826.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $6,572.68 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Novo Nordisk INC | $885.27 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $516.97 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $316.64 | 2019-2025 | Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $287.21 | 2023-2025 | |
| Esperion Therapeutics, INC. | $228.24 | 2022 | |
| Merck Sharp & Dohme LLC | $222.16 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Amgen INC. | $195.10 | 2024-2025 | Krystexxa, Repatha |
| Pfizer INC. | $194.70 | 2022-2025 | |
| Sanofi Pasteur INC. | $165.62 | 2019-2025 | |
| Abiomed | $148.39 | 2023 | Impella |
| Horizon Therapeutics Plc | $125.59 | 2022 | |
| Idorsia Pharmaceuticals US INC | $125.00 | 2023 | Quviviq |
| Boston Scientific Corporation | $123.14 | 2021 | |
| Amarin Pharma, INC. | $122.51 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $121.26 | 2022-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $119.20 | 2024-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $103.40 | 2024-2025 | Farxiga |
| Inspire Medical Systems, INC. | $89.05 | 2024-2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $41.59 | 2025 | |
| Abbvie INC. | $39.52 | 2021 | |
| Hologic Sales and Service, LLC | $38.95 | 2021-2023 | Aptima, Thinprep 2000 Processor |
| Astellas Pharma US INC | $22.59 | 2024 | Veozah |
| Inari Medical, INC. | $18.91 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Phadia US INC. | $16.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saul Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.